Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
5.81
+0.35 (6.42%)
Nov 5, 2024, 1:19 PM EST - Market open
Orchestra BioMed Holdings Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 |
Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Revenue | 2.08 | 2.76 | 3.53 | -0.78 | 5.7 |
Revenue Growth (YoY) | -52.15% | -21.88% | - | - | - |
Cost of Revenue | 0.17 | 0.19 | 0.21 | 0.2 | 0.15 |
Gross Profit | 1.91 | 2.57 | 3.32 | -0.98 | 5.56 |
Selling, General & Admin | 22.89 | 20.26 | 14.03 | 7.93 | 10.83 |
Research & Development | 37.31 | 33.82 | 21.95 | 12.89 | 13.48 |
Operating Expenses | 60.2 | 54.08 | 35.98 | 20.82 | 24.31 |
Operating Income | -58.29 | -51.51 | -32.66 | -21.8 | -18.75 |
Interest Expense | - | - | - | -0.93 | - |
Interest & Investment Income | 3.94 | 3.85 | 0.05 | - | 0.33 |
Other Non Operating Income (Expenses) | -0.01 | -0.29 | -1.35 | 0.7 | -0.18 |
EBT Excluding Unusual Items | -54.36 | -47.95 | -33.96 | -22.03 | -18.6 |
Gain (Loss) on Sale of Investments | -0.07 | -0.02 | 1.03 | -0.99 | -2.75 |
Other Unusual Items | -1.15 | -1.15 | -0.68 | - | - |
Pretax Income | -55.58 | -49.12 | -33.61 | -23.01 | -21.36 |
Net Income | -55.58 | -49.12 | -33.61 | -23.01 | -21.36 |
Net Income to Common | -55.58 | -49.12 | -33.61 | -23.01 | -21.36 |
Shares Outstanding (Basic) | 36 | 33 | 15 | 2 | 2 |
Shares Outstanding (Diluted) | 36 | 33 | 15 | 2 | 2 |
Shares Change (YoY) | 66.07% | 121.67% | 609.97% | 4.86% | - |
EPS (Basic) | -1.57 | -1.48 | -2.24 | -10.90 | -10.61 |
EPS (Diluted) | -1.57 | -1.48 | -2.24 | -10.90 | -10.61 |
Free Cash Flow | -44.71 | -46.21 | -29.88 | -19.7 | -26.72 |
Free Cash Flow Per Share | -1.26 | -1.39 | -1.99 | -9.33 | -13.27 |
Gross Margin | 92.02% | 93.26% | 94.03% | - | 97.46% |
Operating Margin | -2803.61% | -1866.16% | -924.34% | - | -328.81% |
Profit Margin | -2673.26% | -1779.71% | -951.26% | - | -374.45% |
Free Cash Flow Margin | -2150.41% | -1674.09% | -845.74% | - | -468.56% |
EBITDA | -58 | -51.22 | -32.44 | -21.62 | -18.62 |
D&A For EBITDA | 0.29 | 0.29 | 0.22 | 0.18 | 0.14 |
EBIT | -58.29 | -51.51 | -32.66 | -21.8 | -18.75 |
Revenue as Reported | 2.08 | 2.76 | 3.53 | -0.78 | 5.7 |
Source: S&P Capital IQ. Standard template.
Financial Sources.